WNT5A and benign prostatic hyperplasia: Our study results, indicating lower expression of β-catenin, Fzd8, Wnt5a and cyclin D1, may suggest attenuated activity of the Wnt/β-catenin pathway in prostate adenocarcinoma compared to benign prostatic hyperplasia.